Posted by SLS on September 17, 2015, at 20:03:22
In reply to Paroxetine warnings for adolescents + kids new iss, posted by Phillipa on September 17, 2015, at 17:52:32
> http://www.medscape.com/viewarticle/851139
This is what I'm thinking right now:
1. Imipramine is more effective in depression than is placebo. Any study that does not demonstrate this is a failed study. I don't think that any data produced by such a study can be deemed reliable.
2. Paroxetine is more apt to produce suicidal states in young people than are the other marketed SSRIs.
3. Paroxetine is more apt to produce suicidal states in younger people than in older people.
4. Paroxetine, when it fails to produce an antidepressant response, is more apt to produce suicidal states than is placebo.
5. Paroxetine is more effective in depression and anxiety disorders than is placebo in both adults and young people.
6. Paroxetine is more apt to produce suicidal states than imipramine.
7. Paroxetine is more effective in anxiety disorders than are other SSRIs.
8. For any antidepressant, some severely anergic or psychomotor-retarded depressed people who begin to respond favorably to treatment will feel more suicidal during the first 3 weeks of improvement, when mental energy returns without a commensurate improvement in mood or outlook. In these cases, an antidepressant will be more likely to trigger suicidality than placebo.
9. Doctors need to inform their patients that an antidepressant can make them feel worse, and that they must contact the doctor immediately should this occur.
10. Doctors need to monitor their patients closely early in treatment. Seeing a patient every week or every two weeks seems prudent.
Using medication to treat mental illness is not an easy decision to make. There are a great many factors to take into consideration.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1082601
URL: http://www.dr-bob.org/babble/20150901/msgs/1082622.html